Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 18/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL605479 | 0.96 | ADRB1 (0.46) | ADRB1HRH4HTR2C | |
| Trifluoroacetic Acid SCHEMBL9105391 | 0.91 | ADRB1 (0.40) | ADRB1HRH4 | |
| SCHEMBL9884156 | 0.90 | ADRB1 (0.37) | ADRB1HRH4 | |
| Trifluoroacetic Acid SCHEMBL4126873 | 0.88 | ADRB1 (0.40) | ADRB1HRH4 | |
| SCHEMBL605437 | 0.86 | HRH4 (0.48) | HRH4 | |
| SCHEMBL604820 | 0.84 | HRH4 (0.32) | ADRB1HRH4 | |
| SCHEMBL9883840 | 0.84 | HRH4 (0.32) | ADRB1HRH4 | |
| SCHEMBL604041 | 0.83 | HRH3 (0.34) | HRH4 | |
| SCHEMBL602877 | 0.83 | ADRB1 (0.48) | ADRB1HRH4HTR2C | |
| SCHEMBL602845 | 0.81 | HRH3 (0.46) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200595-B1 | THIENO-AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-20 | — | — | EP | claimed |
| US-8445482-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-21 | — | — | US | claimed |
| US-20120270855-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | EDWARDS JAMES P (US) | 2012-10-25 | — | — | US | claimed |
| US-20120238544-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Timoneda, Jesús Joanós i | 2012-09-20 | — | — | US | claimed |
| US-20120214792-A1 | THIENO- ADN FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | EDWARDS JAMES P (US) | 2012-08-23 | — | — | US | claimed |
| US-20120208793-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Timoneda, Jesús Joanós | 2012-08-16 | — | — | US | claimed |
| EP-2200595-A2 | THIENO-AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2010-06-30 | — | — | EP | claimed |
| WO-2009038673-A2 | THIENO-AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-26 | — | — | WO | claimed |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | claimed |
| US-8937075-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8937075-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8927555-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2015-01-06 | — | — | US | disclosed |
| US-8927555-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2015-01-06 | — | — | US | disclosed |
| US-8445482-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-21 | — | — | US | disclosed |
| US-20120208793-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Timoneda, Jesús Joanós | 2012-08-16 | — | — | US | disclosed |
| US-8193178-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-05 | — | — | US | disclosed |
| US-8193178-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-05 | — | — | US | disclosed |
| WO-2009038673-A2 | THIENO-AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-26 | — | — | WO | disclosed |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208793-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | ADRB1 351/4885HRH4 1/4885HTR2C 61/4885 |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | ADRB1 351/4885HRH4 1/4885HTR2C 61/4885 |
| US-20120238544-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | ADRB1 351/4885HRH4 1/4885HTR2C 61/4885 |
| US-20120214792-A1 | THIENO- ADN FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | ADRB1 248/4885HRH4 1/4885HTR2C 65/4885 |
| US-20120270855-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | ADRB1 351/4885HRH4 1/4885HTR2C 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.